This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

The Results of the Lipid Research Clinics Prevalence Cohort

Steven A. Grover, MD, MPA, FRCPC; Cynthia S. Palmer, MSc; Louis Coupal, MSc

Arch Intern Med. 1994;154(6):679-684.

Abstract
Objective
To assess the accuracy of specific plasma lipid fractions in predicting coronary heart disease (CHD) mortality among adults.

Methods
Follow-up data for a random sample of 30- to 79-year-old men and women recruited into the Lipid Research Clinics Prevalence and Follow-up Studies were included in this analysis (n=4499). Baseline measurements of total plasma cholesterol and lipoprotein fractions were compared with subsequent CHD mortality after a mean follow-up of 12.3 years. The areas under receiver operating characteristic curves for specific serum lipids were compared for individuals aged 30 to 59 and 60 to 79 years.

Main Results
For the younger cohort, the ratio of total cholesterol to high-density lipoprotein cholesterol was a better predictor (P<.05) of CHD mortality (receiver operating characteristic curve area, 0.80±0.03) than was total cholesterol level alone (receiver operating characteristic curve area, 0.73±0.03) or any other single lipoprotein measurement. Among the older cohort, the same screening strategies performed poorly, with receiver operating characteristic curve areas ranging from 0.51±0.05 for total cholesterol to 0.64±0.05 for the ratio of low-density to high-density lipoprotein cholesterol levels.

Conclusion
Plasma lipid levels are poor predictors of coronary death among those aged 60 to 79 years without known CHD. These data indicate the need to define better lipid screening strategies for older, asymptomatic adults. Among younger adults aged 30 to 59 years, high-density lipoprotein cholesterol measurement should be included as part of any lipid screening program, as the ratio of total to high-density lipoprotein cholesterol levels is the best lipid screening test to identify those at high risk for subsequent CHD mortality.

(Arch Intern Med. 1994;154:679-684)

Author Affiliations
From the Centre for the Analysis of Cost-Effective Care (Dr Grover, Ms Palmer, and Mr Coupal), the Centre for Cardiovascular Risk Assessment (Dr Grover, Ms Palmer, and Mr Coupal), the Division of Clinical Epidemiology (Dr Grover, Ms Palmer, and Mr Coupal), and the Division of General Internal Medicine (Dr Grover), Montreal (Quebec) General Hospital; and the Departments of Medicine and Epidemiology and Biostatistics, McGill University, Montreal (Dr Grover).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Changes in Lipid Profile Between Flare and Remission of Patients with Systemic Lupus Erythematosus: A Prospective Study
URQUIZU-PADILLA et al.
The Journal of Rheumatology 2009;36:1639-1645.
ABSTRACT | FULL TEXT  

Rhesus Positivity and Low High-Density Lipoprotein Cholesterol: A New Link?
Kanbay et al.
Asian Cardiovasc. Thorac. Ann. 2006;14:119-122.
ABSTRACT | FULL TEXT  

Risk factors for cardiovascular disease in patients with periodontitis
Buhlin et al.
Eur Heart J 2003;24:2099-2107.
ABSTRACT | FULL TEXT  

A Comparison of the Effects of Nevirapine and Nelfinavir on Metabolism and Body Habitus in Antiretroviral-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Controlled Study
Fisac et al.
J. Clin. Endocrinol. Metab. 2003;88:5186-5192.
ABSTRACT | FULL TEXT  

Relative Androgen Excess and Increased Cardiovascular Risk after Menopause: A Hypothesized Relation
Liu et al.
Am J Epidemiol 2001;154:489-494.
ABSTRACT | FULL TEXT  

How Cost-Effective Is the Treatment of Dyslipidemia in Patients With Diabetes but Without Cardiovascular Disease?
Grover et al.
Diabetes Care 2001;24:45-50.
ABSTRACT | FULL TEXT  

Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines
Grover et al.
CMAJ 2000;163:1263-1269.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Treating Hyperlipidemia in the Presence of Diabetes : Who Should Be Treated?
Grover et al.
Circulation 2000;102:722-727.
ABSTRACT | FULL TEXT  

Comparison of a New Method for the Direct and Simultaneous Assessment of LDL- and HDL-Cholesterol with Ultracentrifugation and Established Methods
Benlian et al.
Clin. Chem. 2000;46:493-505.
ABSTRACT | FULL TEXT  

Cost-effectiveness of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors in the Secondary Prevention of Cardiovascular Disease: Forecasting the Incremental Benefits of Preventing Coronary and Cerebrovascular Events
Grover et al.
Arch Intern Med 1999;159:593-600.
ABSTRACT | FULL TEXT  

Maximizing the Cost-effectiveness of Lipid-Lowering Therapy
Jacobson et al.
Arch Intern Med 1998;158:1977-1989.
ABSTRACT | FULL TEXT  

Treating Hyperlipidemia for the Primary Prevention of Coronary Disease: Are Higher Dosages of Lovastatin Cost-effective?
Perreault et al.
Arch Intern Med 1998;158:375-381.
ABSTRACT | FULL TEXT  

Identifying Adults at Increased Risk of Coronary Disease: How Well Do the Current Cholesterol Guidelines Work?
Grover et al.
JAMA 1995;274:801-806.
ABSTRACT  

Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study
Grover et al.
BMJ 1995;310:975-978.
ABSTRACT | FULL TEXT  

The Cost-effectiveness of HMG-CoA Reductase Inhibitors to Prevent Coronary Heart Disease: Estimating the Benefits of Increasing HDL-C
Hamilton et al.
JAMA 1995;273:1032-1038.
ABSTRACT  

PREDICTIVE VALUE OF LIPID SCREENING IN YOUNGER VS. OLDER ADULTS
JWatch General 1994;1994:3-3.
FULL TEXT